PPAR𝛾 and Agonists against Cancer: Rational Design of Complementation Treatments
PPAR𝛾 is a member of the ligand-activated nuclear receptor superfamily: its ligands act as insulin sensitizers and some are approved for the treatment of metabolic disorders in humans. PPAR𝛾 has pleiotropic effects on survival and proliferation of multiple cell types, including cancer cells, and is...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/945275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|